Granisetron in the treatment of obsessive-compulsive disorder

Granisetron in the treatment of obsessive-compulsive disorder: a double-blind, placebo controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202041556N32

Enrollment

Registered

2012-02-06

Start date

2011-11-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive- Cumpulsive Disorder. Obsessive- Cumpulsive Disorder

Interventions

Intervention 1: Tablet fluvoxamine (200 mg/day) combined with 2 mg/day of Tablets granisetron as intervention group for 8 weeks. Intervention 2: Tablet fluvoxamine (200 mg/day) combined with placebo a

Treatment - Drugs

Placebo

Tablet fluvoxamine (200 mg/day) combined with 2 mg/day of Tablets granisetron as intervention group for 8 weeks

Tablet fluvoxamine (200 mg/day) combined with placebo as control group for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria:Age between 18-60; Diagnosis of OCD based on DSM IV; Minimum Score of 21 on YALE-BROWN Obsessive-Compulsive Scale- Exclusion Criteria: Substance dependence; IQ <70; any other mental disorder on axis I; Any serious cardiac, renal or hepatic disease ; receiving psychotropic medications during the last 6 weeks ; pregnancy orbreast feeding; rising liver transaminases to three times the upper limit of normal or higher

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of symptoms of OCD. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: by Y-BOCS Rating Scale.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 25, 2026